Department of Otorhinolaryngology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Division of Clinical Epidemiology, Department of Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Otolaryngol Head Neck Surg. 2023 Oct;169(4):765-779. doi: 10.1002/ohn.327. Epub 2023 Mar 16.
To assess the effect of the pneumococcal vaccine (PCV) toward the surgical management and complications of otitis media.
MEDLINE, EMBASE, PubMed, Scopus, and clinicaltrial.gov.
A systematic search was performed using a combination of keywords and standardized terms about PCV and surgical management or complications of otitis media. Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, studies were screened by 3 independent reviewers. Risk of bias assessment, followed by meta-analysis in only randomized-controlled trials was conducted. Vaccine efficacy (VE) and 95% confidence interval (CI) were reported.
Of the 2649 abstracts reviewed, 27 studies were included in the qualitative analysis and were categorized into 6 outcomes: tympanostomy tube insertion, otitis media with effusion (OME), mastoiditis, spontaneous tympanic membrane (TM) perforation, recurrent acute otitis media (AOM), and severe AOM. Fifteen studies were included in the meta-analysis to evaluate the rate of tympanostomy tube insertion, OME, and recurrent AOM. PCV was significantly more effective in lowering the rate of tympanostomy tube insertion (VE, 22.2%; 95% CI, 14.6-29.8) and recurrent AOM (VE, 10.06%; 95% CI, 7.46-12.65) when compared with the control group, with no significant difference in reducing the incidence of OME. The qualitative analysis revealed that PCV had efficacy in preventing severe AOM and spontaneous TM perforation but the effect on mastoiditis remained unclear.
The PCV was effective in reducing the rate of tympanostomy tube insertion and the incidence of recurrent AOM with a nonsignificant effect in preventing OME in children.
评估肺炎球菌疫苗(PCV)对中耳炎手术治疗和并发症的影响。
MEDLINE、EMBASE、PubMed、Scopus 和 clinicaltrial.gov。
采用肺炎球菌疫苗和中耳炎手术治疗或并发症相关的关键词和标准化术语组合,进行系统检索。根据系统评价和荟萃分析的首选报告项目,由 3 名独立评审员筛选研究。进行风险偏倚评估后,仅对随机对照试验进行荟萃分析。报告疫苗效力(VE)和 95%置信区间(CI)。
在审查的 2649 篇摘要中,有 27 项研究纳入定性分析,并分为 6 个结果:鼓膜切开术置管、分泌性中耳炎(OME)、乳突炎、自发性鼓膜穿孔、复发性急性中耳炎(AOM)和重度 AOM。有 15 项研究纳入荟萃分析,以评估鼓膜切开术置管、OME 和复发性 AOM 的发生率。与对照组相比,PCV 显著降低鼓膜切开术置管(VE,22.2%;95%CI,14.6-29.8)和复发性 AOM(VE,10.06%;95%CI,7.46-12.65)的发生率,而对 OME 的发生率无显著差异。定性分析表明,PCV 在预防重度 AOM 和自发性鼓膜穿孔方面有效,但对乳突炎的效果尚不清楚。
PCV 可有效降低儿童鼓膜切开术置管率和复发性 AOM 发生率,对 OME 的预防效果不显著。